← Back to all trials
Completed
NCT04686175
Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency
Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Sex: All
Ages: 18 Years – 64 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 13
Sponsor: Inozyme Pharma
Location: Mayo Clinic Rochester Minnesota
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of INZ-701, an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy, for the treatment of ENPP1 Deficiency. The goal of the study is to identify a dose regimen for further clinical development in the treatment of ENPP1 Deficiency.
Eligibility Criteria
Individuals eligible to participate must meet all of the following inclusion criteria:
1. Must provide written or electronic consent after the nature of the study has been explained, and prior to any research-related procedures, per International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)
2. Clinical diagnosis of ENPP1 Deficiency supported by prior identification of biallelic ENPP1 mutations (ie, homozygous or compound heterozygous)
3. Male or female, 18 to \
Source: ClinicalTrials.gov (NCT04686175). StuddyBuddy aggregates publicly available trial information.